OpGen
CareDx, Castle Bio, Lucira Health, Others Announce Preliminary Q4, FY21 Earnings Results
CareDx's Q4 revenues rose between 34 percent and 35 percent, while OpGen Q4 revenues were flat compared to the previous year.
OpGen Q3 Revenues Climb 9 Percent
The company attributed the revenue increase to greater sales of its Unyvero molecular diagnostics system and tests.
OpGen Receives FDA Clearance for AMR Panel, Prelim Q3 Revenues Up 9 Percent
The firm's Acuitas AMR Gene Panel tests for 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogens.
OpGen Q2 Revenues Fall 32 Percent
The decline was driven by the dissolution of the firm's FISH business and the completion of an R&D project at subsidiary Ares Genetics.
Mar 25, 2021
OpGen Fourth Quarter Revenues Increase 64 Percent
Feb 9, 2021
OpGen Enters $25M Direct Offering Agreement
Jan 13, 2021
OpGen Preliminary Q4 Revenue Climbs 63 Percent
Nov 24, 2020
OpGen Inks $10M Private Placement Agreement
Aug 20, 2020
OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit
Aug 12, 2020
OpGen Q2 Revenues Climb 20 Percent
Jul 15, 2020
OpGen Preliminary Q2 Revenues Increase 20 Percent
May 7, 2020
OpGen Q1 Revenues Drop 38 Percent
Apr 14, 2020
OpGen Q1 Preliminary Revenues Down 38 Percent
Mar 24, 2020